Business

BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

- Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8

articleBridgebio Pharma, Inc.July 17, 20235/company/bridgebio-pharma-inc/news/bridgebio-announces-consistently-positive-results-from-phase-3-attribute-cm-study-of
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

About this update from Bridgebio Pharma, Inc.

[{"type":"text","content":"- Highly statistically significant result observed on primary endpoint with a Win Ratio of 1.8 (p","length":152,"tagName":"div"}]

More updates from Bridgebio Pharma, Inc.